Challenges in pulmonary hypertension associated with left heart disease

References

• Grossman W. Clinical measurement of vascular resistance and assessment of vasodilator drugs. In: Grossman W, Baim DS, editors. Cardiac catheterization, angiography, and intervention. Philadelphia, Pa: Lea & Febiger; 1991. p. 143–151.
   Google Scholar
• Harris P, Segel N, Bishop J. The Relation between pressure and flow in the pulmonary circulation in normal subjects and in patients with chronic bronchitis and mitral stenosis. Cardiovasc Res. 1968;2(1):73–83.
   Web of Science ®Google Scholar
• Galiè N, McLaughlin VV, Rubin LJ, et al. An overview of the 6th world symposium on pulmonary hypertension. Eur Respir J. 2019; 53(1).
   Web of Science ®Google Scholar
• Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37(1):67–119.
   PubMed Web of Science ®Google Scholar
• Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2013;62:D34–D41.
   PubMed Web of Science ®Google Scholar
• Rosenkranz S. Pulmonary hypertension 2015: current definitions, terminology, and novel treatment options. Clin Res Cardiol. 2015;104:197–207.
   PubMed Web of Science ®Google Scholar
• Guazzi M, Arena R. Pulmonary hypertension with left-sided heart disease. Nat Rev Cardiol. 2010;7:648–659.
   PubMed Web of Science ®Google Scholar
• Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2009;54(Suppl. 1):S43–S54.
   PubMed Web of Science ®Google Scholar
• Guazzi M, Borlaug BA. Pulmonary hypertension due to left heart disease. Circulation. 2012;126:975–990.
   PubMedGoogle Scholar
• Haddad F, Kudelko K, Mercier O, et al. Pulmonary hypertension associated with left heart disease: characteristics, emerging concepts, and treatment strategies. Prog Cardiovasc Dis. 2011;54:154–167.
   PubMed Web of Science ®Google Scholar
• Bursi F, McNallan SM, Redfield MM, et al. Pulmonary pressures and death in heart failure: a community study. J Am Coll Cardiol. 2012;59:222–231.
   PubMed Web of Science ®Google Scholar
• Fang JC, DeMarco T, Givertz MM, et al. World health organization pulmonary Hypertension group 2: pulmonary hypertension due to left heart disease in the adult–a summary statement from the pulmonary hypertension council of the international society for heart and lung transplantation. J Heart Lung Transplant. 2012;31(9):913–933.
   PubMed Web of Science ®Google Scholar
• Abel FL, Waldhausen JA. Waldhausen JA Effects of alterations in pulmonary vascular resistance on right ventricular function. J Thorac Cardiovasc Surg. 1967;54(6):886–894.
   PubMed Web of Science ®Google Scholar
• Schrier RW, Bansal S. Pulmonary hypertension, right ventricular failure, and kidney: different from left ventricular failure?. Clin J Am Soc Nephrol. 2008;3:1232–1237.
   PubMed Web of Science ®Google Scholar
• Thenappan T, Gomberg-Maitland M. Epidemiology of pulmonary hypertension and right ventricular failure in left heart failure. Curr Heart Fail Rep. 2014;11:428–435.
   PubMedGoogle Scholar
• Kjaergaard J, Akkan D, Iversen KK, et al. Prognostic importance of pulmonary hypertension in patients with heart failure. Am J Cardiol. 2007;99:1146–1150.
   PubMed Web of Science ®Google Scholar
• Gerges M, Gerges C, Pistritto A-M, et al. Pulmonary hypertension in heart failure. Epidemiology, right ventricular function, and survival. Am J Respir Crit Care Med. 2015;192(10):1234–1246.
   PubMed Web of Science ®Google Scholar
• Miller WL, Grill DE, Borlaug BA. Clinical features, hemodynamics, and outcomes of pulmonary hypertension due to chronic heart failure with reduced ejection fraction: pulmonary hypertension and heart failure. JACC Heart Fail. 2013;1:290–299.
   PubMed Web of Science ®Google Scholar
• Cappola TP, Felker GM, Kao WH, et al. Pulmonary hypertension and risk of death in cardiomyopathy: patients with myocarditis are at higher risk. Circulation. 2002;105(14):1663–1668.
   PubMed Web of Science ®Google Scholar
• Szwejkowski BR, Elder DH, Shearer F, et al. Pulmonary hypertension predicts all-cause mortality in patients with heart failure: a retrospective cohort study. Eur J Heart Fail. 2012;14:162–167.
   Web of Science ®Google Scholar
• Miller WL, Mahoney DW, Michelena HI, et al. Contribution of ventricular diastolic dysfunction to pulmonary hypertension complicating chronic systolic heart failure. JACC Cardiovasc Imaging. 2011;4:946–954.
   PubMed Web of Science ®Google Scholar
• Abramson SV, Burke JF, Kelly JJ, et al. Pulmonary hypertension predicts mortality and morbidity in patients with dilated cardiomyopathy. Ann Intern Med. 1992;116:888–895.
   PubMed Web of Science ®Google Scholar
• Ghio S, Gavazzi A, Campana C, et al. Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. J Am Coll Cardiol. 2001;37:183–188.
   PubMed Web of Science ®Google Scholar
• Burke MA, Katz DH, Beussink L, et al. Prognostic importance of pathophysiologic markers in patients with heart failure and preserved ejection fraction. Circ Heart Fail. 2014;7:288–299.
   PubMed Web of Science ®Google Scholar
• Lam CS, Roger VL, Rodeheffer RJ, et al. Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. J Am Coll Cardiol. 2009;53:1119–1126.
   PubMed Web of Science ®Google Scholar
• Mohammed SF, Hussain I, AbouEzzeddine OF, et al. Right ventricular function in heart failure with preserved ejection fraction: a community-based study. Circulation. 2014;130:2310–2320.
   PubMed Web of Science ®Google Scholar
• Anjan VY, Loftus TM, Burke MA, et al. Prevalence, clinical phenotype, and outcomes associated with normal b-type natriuretic peptide levels in heart failure with preserved ejection fraction. Am J Cardiol. 2012;110:870–876.
   PubMed Web of Science ®Google Scholar
• Leung CC, Moondra V, Catherwood E, et al. Prevalence and risk factors of pulmonary hypertension in patients with elevated pulmonary venous pressure and preserved ejection fraction. Am J Cardiol. 2010;106:284–286.
   PubMed Web of Science ®Google Scholar
• Shah AM, Shah SJ, Anand IS, et al. Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circ Heart Fail. 2014;7:104–115.
   PubMed Web of Science ®Google Scholar
• Mentias A, Patel K, Patel H, et al. Effect of pulmonary vascular pressures on long-term outcome in patients with primary mitral regurgitation. J Am Coll Cardiol. 2016;67(25):2952–2961.
   PubMed Web of Science ®Google Scholar
• Rich S, Rabinovitch M. Diagnosis and treatment of secondary (non-category 1) pulmonary hypertension. Circulation. 2008;118(21):2190–2199.
   PubMed Web of Science ®Google Scholar
• Oudiz RJ. Pulmonary hypertension associated with left-sided heart disease. Clin Chest Med. 2007;28(1):233–241.
   PubMed Web of Science ®Google Scholar
• Pietra GG, Capron F, Stewart S, et al. Pathologic assessment of vasculopathies in pulmonary hypertension. J Am Coll Cardiol. 2004;43(12 Suppl S):25S–32S.
   PubMed Web of Science ®Google Scholar
• Hanif W, Alex L, Ya S, et al. Left atrial remodeling, hypertrophy and fibrosis in mouse models of heart failure. Cardiovasc Pathol. 2017;30:27–37.
   PubMed Web of Science ®Google Scholar
• West JB, Mathieu-Costello O. Vulnerability of pulmonary capillaries in heart disease. Circulation. 1995;92:622–631.
   PubMed Web of Science ®Google Scholar
• Conforti E, Fenoglio C, Bernocchi G, et al. Morpho-functional analysis of lung tissue in mild interstitial edema. Am J Physiol Lung Cell Mol Physiol. 2002;282:L766–L774.
   PubMed Web of Science ®Google Scholar
• Tsukimoto K, Mathieu-Costello O, Prediletto R, et al. Ultrastructural appearances of pulmonary capillaries at high transmural pressures. J Appl Physiol. 1991;71:573–582.
   PubMed Web of Science ®Google Scholar
• Townsley MI, Fu Z, Mathieu-Costello O, et al. Pulmonary microvascular permeability. Responses to high vascular pressure after induction of pacing-induced heart failure in dogs. Circ Res. 1995;77:317–325.
   PubMed Web of Science ®Google Scholar
• Guazzi M. Alveolar gas diffusion abnormalities in heart failure. J Card Fail. 2008;14:695–702.
   PubMed Web of Science ®Google Scholar
• Kapanci Y, Burgan S, Pietra GG, et al. Modulation of actin isoform expression in alveolar myofibroblasts (contractile interstitial cells) during pulmonary hypertension. Am J Pathol. 1990;136:881–889.
   PubMed Web of Science ®Google Scholar
• Kim KK, Kugler MC, Wolters PJ, et al. Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix. Proc Natl Acad Sci U S A. 2006;103:13180–13185.
   PubMed Web of Science ®Google Scholar
• Harris P, Heath D. The human pulmonary circulation: its form and function in health and disease. Livingstone, Edinburgh, United Kingdom: E. & S; 1962.
   Google Scholar
• Tandon HD, Kasturi J. Pulmonary vascular changes associated with isolated mitral stenosis in India. Br Heart J. 1975;37:26–36.
   PubMedGoogle Scholar
• Chen DD, Dong YG, Yuan H, et al. Endothelin 1 activation of endothelin A receptor/NADPH oxidase pathway and diminished antioxidants critically contribute to endothelial progenitor cell reduction and dysfunction in salt-sensitive hypertension. Hypertension. 2012;59:1037–1043.
   PubMed Web of Science ®Google Scholar
• Cooper CJ, Jevnikar FW, Walsh T, et al. The influence of basal nitric oxide activity on pulmonary vascular resistance in patients with congestive heart failure. Am J Cardiol. 1998;82:609–614.
   PubMed Web of Science ®Google Scholar
• Ooi H, Colucci WS, Givertz MM. Endothelin mediates increased pulmonary vascular tone in patients with heart failure: demonstration by direct intrapulmonary infusion of sitaxsentan. Circulation. 2002;106:1618–1621.
   PubMed Web of Science ®Google Scholar
• Vachiery JL, Adir Y, Barbera JA, et al. Pulmonary hypertension due to left heart diseases. J Am Coll Cardiol. 2013;62(Suppl D):D100–D108.
   PubMedGoogle Scholar
• Ten Freyhaus H, Dagnell M, Leuchs M, et al. Hypoxia enhances PDGF signaling in the pulmonary vasculature by downregulation of protein tyrosine phosphatases. Am J Respir Crit Care Med. 2011;183:1092–1102.
   PubMed Web of Science ®Google Scholar
• Cargill RI, Lipworth BJ. Lisinopril attenuates acute hypoxic pulmonary vasoconstriction in humans. Chest. 1996;109(2):424–429.
   PubMed Web of Science ®Google Scholar
• Ferreira AJ, Shenoy V, Yamazato Y, et al. Evidence for angiotensin-converting enzyme 2 as a therapeutic target for the prevention of pulmonary hypertension. Am J Respir Crit Care Med. 2009;179(11):1048–1054.
   PubMed Web of Science ®Google Scholar
• Kutty RS, Parameshwar J, Lewis C, et al. Use of centrifugal left ventricular assist device as a bridge to candidacy in severe heart failure with secondary pulmonary hypertension. Eur J Cardiovasc Surg. 2013;43:1237–1242.
   Google Scholar
• Lundgren J, Algotsson L, Kornhall B, et al. Preoperative pulmonary hypertension and its impact on survival after heart transplantation. Scand Cardiovasc J. 2014;48:47–58.
   PubMed Web of Science ®Google Scholar
• Wood P. Pulmonary hypertension with special reference to the vasoconstrictive factor. Br Heart J. 1958;20:557–570.
   PubMedGoogle Scholar
• Naeije R, Vachiery JL, Yerly P, et al. The transpulmonary pressure gradient for the diagnosis of pulmonary vascular disease. Eur Respir J. 2013;41:217–223.
   PubMed Web of Science ®Google Scholar
• Gerges C, Gerges M, Lang MB, et al. Diastolic pulmonary vascular pressure gradient: a predictor of prognosis in “out-of-proportion” pulmonary hypertension. Chest. 2013;143(3):758–766.
   PubMed Web of Science ®Google Scholar
• Rapp AH, Lange RA, Cigarroa JE, et al. Relation of pulmonary arterial diastolic and mean pulmonary arterial wedge pressures in patients with and without pulmonary hypertension. Am J Cardiol. 2001;88:823–824.
   PubMed Web of Science ®Google Scholar
• O’Sullivan CJ, Wenaweser P, Ceylan O, et al. Effect of pulmonary hypertension hemodynamic presentation on clinical outcomes in patients with severe symptomatic aortic valve stenosis undergoing transcatheter aortic valve implantation: insights from the new proposed pulmonary hypertension classification. Circ Cardiovasc Interv. 2015;8:e002358.
   PubMed Web of Science ®Google Scholar
• Brunner NW, Yue SF, Stub D, et al. The prognostic importance of the diastolic pulmonary gradient, transpulmonary gradient, and pulmonary vascular resistance in patients undergoing transcatheter aortic valve replacement. Catheter Cardiovasc Interv. 2017;90:1185–2119.
   PubMed Web of Science ®Google Scholar
• Assad TR, Hemnes AR, Larkin EK, et al. Clinical and biological insights into combined post- and pre-capillary pulmonary hypertension. J Am Coll Cardiol. 2016;68:2525–2536.
   PubMed Web of Science ®Google Scholar
• Tedford RJ, Beaty CA, Mathai SC, et al. Prognostic value of the pre-transplant diastolic pulmonary artery pressure-to-pulmonary capillary wedge pressure gradient in cardiac transplant recipients with pulmonary hypertension. J Heart Lung Transplant. 2014;33(3):289–297.
   PubMed Web of Science ®Google Scholar
• Tampakakis E, Leary PJ, Selby VN, et al. diastolic pulmonary gradient does not predict survival in patients with pulmonary hypertension due to left heart disease. JACC Heart Fail. 2015;3(1):9–16.
   PubMed Web of Science ®Google Scholar
• Palazzini M, Dardi F, Manes A, et al. Pulmonary hypertension due to left heart disease: analysis of survival according to the haemodynamic classification of the 2015 ESC/ERS guidelines and insights for future changes. Eur J Heart Fail. 2018;20:248–255.
   PubMed Web of Science ®Google Scholar
• Al-Naamani N, Preston IR, Paulus JK, et al. Pulmonary arterial capacitance is an important predictor of mortality in heart failure with a preserved ejection fraction. JACC Heart Fail. 2015;3:467–474.
   PubMed Web of Science ®Google Scholar
• Dragu R, Rispler S, Habib M, et al. Pulmonary arterial capacitance in patients with heart failure and reactive pulmonary hypertension. Eur J Heart Fail. 2015;17:74–80.
   PubMed Web of Science ®Google Scholar
• Vachiéry JL, Tedford RJ, Rosenkranz S, et al. Pulmonary hypertension due to left heart disease. Eur Respir J. 2019;53(1):1801897.
   PubMed Web of Science ®Google Scholar
• Gerges M, Gerges C, Lang IM. How to define pulmonary hypertension due to left heart disease. Eur Respir J. 2016;48(2):553–555.
   PubMed Web of Science ®Google Scholar
• Fujimoto N, Borlaug BA, Lewis GD, et al. Hemodynamic responses to rapid saline loading: the impact of age, sex, and heart failure. Circulation. 2013;127:55–62.
   PubMed Web of Science ®Google Scholar
• Shim CY, Kim SA, Choi D, et al. Clinical outcomes of exercise-induced pulmonary hypertension in subjects with preserved left ventricular ejection fraction: implication of an increase in left ventricular filling pressure during exercise. Heart. 2011;97:1417–1424.
   PubMed Web of Science ®Google Scholar
• Dorfs S, Zeh W, Hochholzer W, et al. Pulmonary capillary wedge pressure during exercise and long-term mortality in patients with suspected heart failure with preserved ejection fraction. Eur Heart J. 2014;35:3103–3112.
   PubMed Web of Science ®Google Scholar
• Champion HC, Michelakis ED, Hassoun PM. Comprehensive invasive and noninvasive approach to the right ventricle-pulmonary circulation unit: state of the art and clinical and research implications. Circulation. 2009;120:992–1007.
   PubMed Web of Science ®Google Scholar
• Tolle JJ, Waxman AB, Van Horn TL, et al. Exercise-induced pulmonary arterial hypertension. Circulation. 2008;118:2183–2189.
   PubMed Web of Science ®Google Scholar
• Wolsk E, Bakkestrøm R, Thomsen JH, et al. The influence of age on hemodynamic parameters during rest and exercise in healthy individuals. J Am Coll Cardiol HF. 2017;5(5):337–346.
   Google Scholar
• Oliveira RK, Agarwal M, Tracy JA, et al. Age-related upper limits of normal for maximum upright exercise pulmonary haemodynamics. Eur Respir J. 2016;47:1179–1188.
   PubMed Web of Science ®Google Scholar
• Argiento P, Chesler N, Mule M, et al. Exercise stress echocardiography for the study of the pulmonary circulation. Eur Respir J. 2010;35:1273–1278.
   PubMed Web of Science ®Google Scholar
• Reeves JT, Dempsey J, Grover RF. Pulmonary circulation during exercise. In: Wei EK, Reeves JT, editors. Pulmonary vascular physiology and physiopathology. New York: Marcel Dekker; 1989. p. 107–133.
   Google Scholar
• Robbins IM, Hemnes AR, Pugh ME, et al. High prevalence of occult pulmonary venous hypertension revealed by fluid challenge in pulmonary hypertension. Circ Heart Fail. 2014;7:116–122.
   PubMed Web of Science ®Google Scholar
• Andersen MJ, Olson TP, Melenovsky V, et al. Differential hemodynamic effects of exercise and volume expansion in people with and without heart failure. Circ Heart Fail. 2015;8:41–48.
   PubMed Web of Science ®Google Scholar
• D’Alto M, Romeo E, Argiento P, et al. Clinical relevance of fluid challenge in patients evaluated for pulmonary hypertension. Chest. 2017;151:119–126.
   PubMed Web of Science ®Google Scholar
• Yancy CW, Jessup M, Bozkurt B, et al. American College of Cardiology Foundation/American Heart Association task force on practice guidelines. 2013 ACCF/AHA guidelinefor the management of HF: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. Circulation. 2013;128(16):e240–e327.
   PubMed Web of Science ®Google Scholar
• Georgiopoulou VV, Kalogeropoulos AP, Borlaug BA, et al. Left ventricular dysfunction with pulmonary hypertension: part 2: prognosis, noninvasive evaluation, treatment, and future research. Circ Heart Fail. 2013;6(2):344–354.
   PubMed Web of Science ®Google Scholar
• Cooper TJ, Guazzi M. Sildenafil in Heart failure (SilHF). An investigator-initiated multinational randomized controlled clinical trial: rationale and design. Eur J Heart Fail. 2013;15(1):119–122.
   PubMed Web of Science ®Google Scholar
• Galiè N, Corris PA, Frost A, et al. Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol. 2013;62(Suppl D):D60–D72.
   PubMedGoogle Scholar
• Lüscher TF1, Lüscher F, Enseleit F, Pacher R, et al. Heart failure ET(A) receptor blockade trial. Hemodynamic and neurohumoral effects of selective endothelin A (ET(A)) receptor blockade in chronic heart failure: the heart failure ET(A) receptor blockade trial (HEAT). Circulation. 2002;106(21):2666–2672.
   PubMed Web of Science ®Google Scholar
• Califf RM, Adams KF, McKenna WJ, et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: the Flolan International Randomized Survival Trial (FIRST). Am Heart J. 1997;134(1):44–54.
   PubMed Web of Science ®Google Scholar
• Luscher TF, Barton M. Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation. 2000;102(19):2434–2440.
   PubMed Web of Science ®Google Scholar
• Kalra PR, Moon JC, Coats AJ. Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure? Int J Cardiol. 2002;85(2–3):195–197.
   PubMed Web of Science ®Google Scholar
• McMurray JJ, Teerlink JR, Cotter G, et al. VERITAS investigator. Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. Jama. 2007;298(17):2009–2019.
   PubMed Web of Science ®Google Scholar
• Packer M, McMurrayJ J, Massie BM, et al. Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study. Card Faill. 2005;11(1):12–20.
   PubMed Web of Science ®Google Scholar
• Anand I, McMurray J, Cohn JN, et al. EARTH Investigator. Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA receptor antagonist trial in heart failure (EARTH): randomised, double-blind, placebo-controlled trial. Lancet. 2004;364(9431):347–354.
   PubMed Web of Science ®Google Scholar
• Kelland NF, Webb DJ. Clinical trials of endothelin antagonists in heart failure: publication is good for the public health. Heart. 2007;93(1):2–4.
   PubMed Web of Science ®Google Scholar
• Koller B, Steringer-Mascherbauer R, Ebner CH, et al. Pilot study of endothelin receptor blockade in heart failure with diastolic dysfunction and pulmonary hypertension (BADDHY-Trial). Heart Lung Circ. 2017;26(5):433–441.
   PubMed Web of Science ®Google Scholar
• Vachiéry JL, Delcroix M, Al-Hiti H, et al. Macitentan in pulmonary hypertension due to left ventricular dysfunction. Eur Respir J. 2018;51:2.
   Web of Science ®Google Scholar
• Barnett CF, Machado RF. Sildenafil in the treatment of pulmonary hypertension. Vasc Health Risk Manag. 2006;2(4):411–422.
   PubMedGoogle Scholar
• Galiè N, Ghofrani HA, Torbicki A, et al. Sildenafil use in pulmonary arterial hypertension (SUPER) study group. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353(20):2148–2157.
   PubMed Web of Science ®Google Scholar
• Galiè N, Brundage BH, Ghofrani HA, et al. Pulmonary arterial hypertension and response to tadalafil (PHIRST) study group.Tadalafil therapy for pulmonary arterial hypertension. Circulation. 2009;119(22):2894–2903.
   PubMed Web of Science ®Google Scholar
• Kumar P, Francis GS, Tang WH. Phosphodiesterase 5 inhibition in heart failure: mechanisms and clinical implications. Nat Rev Cardiol. 2009;6(5):349–355.
   PubMed Web of Science ®Google Scholar
• Sr G. Type 5 phosphodiesterase inhibition in heart failure: the next step. J Am Coll Cardiol. 2007;50(22):2145–2147.
   PubMed Web of Science ®Google Scholar
• Alaeddini J, Uber PA, Park MH, et al. Efficacy and safety of sildenafil in the evaluation of pulmonary hypertension in severe heart failure. Am J Cardiol. 2004;94(11):1475–1477.
   PubMed Web of Science ®Google Scholar
• Lepore JJ, Maroo A, Bigatello LM, et al. Hemodynamic effects of sildenafil in patients with congestive heart failure and pulmonary hypertension: combined administration with inhaled nitric oxide. Chest. 2005;127(5):1647–1653.
   PubMed Web of Science ®Google Scholar
• Lewis GD, Lachmann J, Camuso J, et al. Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure. Circulation. 2007;115(1):59–66.
   PubMed Web of Science ®Google Scholar
• Guazzi M, Samaja M, Arena R, et al. Long-term use of sildenafil in the therapeutic management of heart failure. J Am Coll Cardiol. 2007;50(22):2136–2144.
   PubMed Web of Science ®Google Scholar
• Guazzi M, Vicenzi M, Arena R, et al. PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebo-controlled study.. Circ Heart Fail. 2011;4(1):8–17.
   PubMed Web of Science ®Google Scholar
• Guazzi M, Vicenzi M, Arena R, et al. Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1 year study. Circulation. 2011;124:164–174.
   PubMed Web of Science ®Google Scholar
• Redfield MM, Chen HH, Borlaug BA, et al. RELAX trial. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. Jama. 2013;309(12):1268–1277.
   PubMed Web of Science ®Google Scholar
• Stasch J-P, Pacher P, Evgenov OV. Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation. 2011;123(20):2263–2273.
   PubMed Web of Science ®Google Scholar
• Bonderman D, Pretsch I, Steringer-Mascherbauer R, et al. Acute hemodynamic effects of riociguat in patients with pulmonary hypertension associated with diastolic heart failure (DILATE-1): a randomized, double-blind, placebo-controlled, single-dose study. Chest. 2014;146(5):1274–1285.
   PubMed Web of Science ®Google Scholar
• Pieske B, Maggioni AP, Lam CSP, et al. Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study. Eur Heart J. 2017;38(15):1119–1127.
   PubMed Web of Science ®Google Scholar
• Packer M, McMurray JJV, Krum H, et al. ENABLE investigators and committees.long-term effect of endothelin receptor antagonism with bosentan on the morbidity and mortality of patients with severe chronic heart failure: primary results of the ENABLE trials. JACC Heart Fail. 2017;5(5):317–326.
   PubMed Web of Science ®Google Scholar
• Guazzi M, Tumminello G, Di Marco F, et al. The effects of phosphodiesterase-5 inhibition with sildenafil on pulmonary hemodynamics and diffusion capacity, exercise ventilatory efficiency, and oxygen uptake kinetics in chronic heart failure. J Am Coll Cardiol. 2004;44(12):2339–2348.
   PubMed Web of Science ®Google Scholar
• Bonderman D, Ghio S, Felix SB, et al. Left Ventricular Systolic Dysfunction Associated With Pulmonary Hypertension Riociguat Trial (LEPHT) study group. Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study. Circulation. 2013;128(5):502–511.
   PubMed Web of Science ®Google Scholar
• Hoendermis ES, Liu LCY, Hummel YM, et al. Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial. Eur Heart J. 2015;36(38):2565–2573.
   PubMed Web of Science ®Google Scholar